The short version of prothymosin alpha fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-06-21. Anything still debated is marked as such rather than presented as settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
| Property | Value | Notes |
|---|---|---|
| Amino acid length | 28 residues | Single chain with an acetylated N-terminus |
| Molecular mass | Approximately 3,108 Da | Small shifts occur with counter-ion and water content |
| Isoelectric point | Around 3.5 | Low value follows from the many acidic residues |
| Parent molecule | N-terminal region of prothymosin alpha | Free circulating form in humans is not firmly established |
| Common synonyms | Thymalfasin; T alpha 1 | Older literature also uses the full spelled-out form |
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
==== Drug delivery ==== Emerging methods of drug delivery involving nanotechnological methods can be useful by improving bodily response, specific targeting, and non-toxic metabolism. Many nanotechnological methods and materials can be functionalized for drug delivery. Ideal materials employ a controlled-activation nanomaterial to carry a drug cargo into the body. Mesoporous silica nanoparticles (MSN) have increased in research popularity due to their large surface area and flexibility for various individual modifications while maintaining high-resolution performance under imaging techniques. Activation methods greatly vary across nanoscale drug delivery molecules, but the most commonly used activation method uses specific wavelengths of light to release the cargo. Nanovalve-controlled cargo release uses low-intensity light and plasmonic heating to release the cargo in a variation of MSN containing gold molecules. The two-photon activated photo-transducer (2-NPT) uses near infrared wavelengths of light to induce the breaking of a disulfide bond to release the cargo. Recently, nanodiamonds have demonstrated potential in drug delivery due to non-toxicity, spontaneous absorption through the skin, and the ability to enter the blood–brain barrier. The unique structure of carbon nanotubes also gives rise to many innovative inventions of new medical methods. As more medicine is made at the nano level to revolutionize the ways for human to detect and treat diseases, carbon nanotubes become a stronger candidate in new detection methods and therapeutic strategies.
=== Transduction === Upon activation by dynorphin, KORs bind to pertussis toxin-sensitive heterotrimeric Gαi proteins, initiating a pattern of signaling events within the cell, including inhibition of adenylate cyclase activity, increase in K+ conductance, decrease in calcium conductance, emptying of intracellular calcium storage. KOR activation is coupled to the G protein Gi/G0, which subsequently increases phosphodiesterase activity. Phosphodiesterases break down cAMP, producing an inhibitory effect in neurons. KORs also couple to inward-rectifier potassium and to N-type calcium ion channels. Studies have also shown that agonist-induced stimulation of the KOR, like other G-protein coupled receptors, can result in the activation of mitogen-activated protein kinases (MAPK). These include extracellular signal-regulated kinase (ERK), p38 mitogen-activated protein kinases, and c-Jun N-terminal kinases.
In the United States vaccination was regulated by individual states, the first to impose compulsory vaccination being Massachusetts in 1809. There then followed sequences of compulsion, opposition and repeal in various states. By 1930 Arizona, Utah, North Dakota and Minnesota prohibited compulsory vaccination, 35 states allowed regulation by local authorities, or had no legislation affecting vaccination, whilst in ten states, including Washington, D.C. and Massachusetts, infant vaccination was compulsory. Compulsory infant vaccination was regulated by only allowing access to school for those who had been vaccinated. Those seeking to enforce compulsory vaccination argued that the public good overrode personal freedom, a view supported by the U.S. Supreme Court in Jacobson v. Massachusetts in 1905, a landmark ruling which set a precedent for cases dealing with personal freedom and the public good. Louis T. Wright, an African-American Harvard Medical School graduate (1915), introduced, while serving in the Army during World War I, intradermal, smallpox vaccination for the soldiers.
2 SO2 + O2 ⇌ 2 SO3 The sulfur trioxide is absorbed into 97–98% H2SO4 to form oleum (H2S2O7), also known as fuming sulfuric acid or pyrosulfuric acid. The oleum is then diluted with water to form concentrated sulfuric acid.
Sources: en.wikipedia.org
A vaccine licensure occurs after the successful conclusion of the development cycle and further the clinical trials and other programs involved through Phases I–III demonstrating safety, immunoactivity, immunogenetic safety at a given specific dose, proven effectiveness in preventing infection for target populations, and enduring preventive effect (time endurance or need for revaccination must be estimated). Because preventive vaccines are predominantly evaluated in healthy population cohorts and distributed among the general population, a high standard of safety is required. As part of a multinational licensing of a vaccine, the World Health Organization Expert Committee on Biological Standardization developed guidelines of international standards for manufacturing and quality control of vaccines, a process intended as a platform for national regulatory agencies to apply for their own licensing process. Vaccine manufacturers do not receive licensing until a complete clinical cycle of development and trials proves the vaccine is safe and has long-term effectiveness, following scientific review by a multinational or national regulatory organization, such as the European Medicines Agency (EMA) or the US Food and Drug Administration (FDA). Upon developing countries adopting WHO guidelines for vaccine development and licensure, each country has its own responsibility to issue a national licensure, and to manage, deploy, and monitor the vaccine throughout its use in each nation.
It disclosed approximately 74,000 families had a child who had been fed melamine-tainted milk, but did not reveal how many of those children had fallen ill as a result. Because of the many months before the scandal was exposed, media suggested the official figures were likely to be understated. Kidney stones in infants started being reported in several parts of China in the two years prior. A number of yet-to-be-officially-acknowledged cases were reported by the media. However, those deaths without an official verdict may be denied compensation. On 1 December 2008 Xinhua reported that the Ministry of Health revised the number of victims to more than 290,000 with 51,900 hospitalized; authorities acknowledged receiving reports of 11 suspected deaths from melamine contaminated powdered milk from provinces, but officially confirmed three deaths. On characterisation and treatment of urinary stones in affected infants, the New England Journal of Medicine printed an editorial in March 2009, along with reports on cases from Beijing, Hong Kong and Taipei. Urinary calculi specimens were collected from 15 cases treated in Beijing and were analysed as unknown objects for their components at Beijing Institute of Microchemistry using infrared spectroscopy, nuclear magnetic resonance, and high-performance liquid chromatography. The result of the analyses showed the calculi were composed of melamine and uric acid, and the molecular ratio of uric acid to melamine was around 2:1.
Lisa Sanders then questions if the episodes could be caused by an increase in stress, rooted by a traumatic stress episode within his early childhood involving custody actions between his mother and father. To help Matt out with the stress and psychological aspect of his illness, he was referred to a psychiatrist at Johns Hopkins that started him on cognitive behavioral therapy. While the cognitive therapy would help Matt out with his internal stress it might also help alleviate the severity of his episode until he is able to secure a valid diagnosis.
== Archaic Hassuna == ‘Archaic Hassuna’ has been introduced more recently as a new period different to proto-Hassuna. This period is recorded to have a decrease in the concentration of dung in ceramic production and an increase in the use of two-layer slabs in construction, although they were used prior to this period. During this timeframe, pottery kilns start to show up in many sites. The changing patterns within pottery may also connect with an increase in cultural diffusion. The type site, Tell Hassuna, is also recorded to possess Archaic Hassuna artifacts. The time frame for this period was about 6300-6000 BC.
== Fertilisation == Most notably, oxidative burst post fertilisation can be seen in the sea urchin egg. This is believed to be evolutionally divergent from that in neutrophils. Hydrogen peroxide is produced by egg oxidase activity following an increase in oxygen consumption. This is essential for the cross-linking of the ovum proteins to prevent lethal polyspermy. Hydrogen peroxide itself is also spermicidal. However, the generated reactive species are maintained at lower levels than in immunity to protect the fertilised egg itself from oxidative damage. This is achieved by the elimination of hydrogen peroxide primarily through the dual function of the same egg oxidase, and secondarily through cytoplasmic ROS scavengers, such as catalase and glutathione.
Sources: en.wikipedia.org
Amphetamine is a methyl homolog of the mammalian neurotransmitter phenethylamine with the chemical formula C9H13N. The carbon atom adjacent to the primary amine is a stereogenic center, and amphetamine is composed of a racemic 1:1 mixture of two enantiomers. This racemic mixture can be separated into its optical isomers: levoamphetamine and dextroamphetamine. At room temperature, the pure free base of amphetamine is a mobile, colorless, and volatile liquid with a characteristically strong amine odor, and acrid, burning taste. Frequently prepared solid salts of amphetamine include amphetamine adipate, aspartate, hydrochloride, phosphate, saccharate, sulfate, and tannate. Dextroamphetamine sulfate is the most common enantiopure salt. Amphetamine is also the parent compound of its own structural class, which includes a number of psychoactive derivatives. In organic chemistry, amphetamine is an excellent chiral ligand for the stereoselective synthesis of 1,1'-bi-2-naphthol.
For interpretation, first, look for single amino acid immonium ions (H2N+=CHR2). Corresponding immonium ions for amino acids are listed in Table 1. Ignore a few peaks at the high-mass end of the spectrum. They are ions that undergo neutral molecules losses (H2O, NH3, CO2, HCOOH) from [M+H]+ ions. Find mass differences at 28 Da since b-ions can form a-ions by loss of CO. Look for b2-ions at low-mass end of the spectrum, which helps to identify yn-2-ions too. Mass of b2-ions are listed in Table 2, as well as single amino acids that have equal mass to b2-ions. The mass of b2-ion = mass of two amino acid residues + 1.
== Interactions == Carbamazepine and other enzyme inducers may reduce plasma levels of risperidone. If a person is taking both carbamazepine and risperidone, the dose of risperidone will likely need to be increased. The new dose should not be more than twice the patient's original dose. CYP2D6 inhibitors, such as the SSRI medications fluoxetine and paroxetine, may increase plasma levels of risperidone. Since risperidone can cause hypotension, its use should be monitored closely when a patient is also taking antihypertensive medicines to avoid severe low blood pressure. Risperidone and its metabolite paliperidone are reduced in efficacy by P-glycoprotein inducers such as St John's wort. Risperidone has been found to dose-dependently block the effects of serotonergic psychedelics like psilocybin and lysergic acid diethylamide (LSD).
29 July – Laura Mackenzie, whose offer of a job with Police Scotland was withdrawn when it emerged she had been prescribed antidepressants, launches legal action against the force. The offer was withdrawn after her medical history came to light during a health examination prior to starting the job, and because Police Scotland requires any recruits to be clear of antidepressant medication for at least two years. 31 July Media outlets, including BBC News, report that a medical student has been expelled from the University of Dundee after filming the dissection of a human body and posting the footage online. The 2023 Rutherglen and Hamilton West recall petition closes. A by-election is triggered after the petition to remove Margaret Ferrier from office is signed by 11,896 of the 81,124 eligible constituents, passing the required 10% threshold.
Sources: en.wikipedia.org
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.
Prothymosin alpha is a much larger acidic protein, roughly 111 to 113 residues long, and the thymosin alpha-1 sequence matches its N-terminal region. The small peptide is therefore best understood as a fragment of that parent protein rather than a separate gene product.
Trials and clinical reports have examined chronic hepatitis B and C, use as a vaccine adjuvant, and supportive treatment in some immunodeficiency and oncology settings. Results vary by indication, and regulatory approval differs between countries.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.